Viatris (VTRS) Capital Expenditures Growth (3y) (2023 - 2026)
Viatris (VTRS) Capital Expenditures Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -4.39% |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | -11.01% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -0.22% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 34.19% |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -8.00% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 4.68% |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | -7.72% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | -5.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.00% |
| Mar 31, 2026 | -5.84% |
| Dec 31, 2025 | 8.53% |
| Sep 30, 2025 | -5.82% |
| Jun 30, 2025 | -14.25% |
| Mar 31, 2025 | -12.91% |
| Dec 31, 2024 | -10.74% |
| Sep 30, 2024 | -13.99% |
| Jun 30, 2024 | -13.00% |
| Mar 31, 2024 | 0.20% |
| Dec 31, 2023 | 12.29% |
| Mar 31, 2023 | 3.27% |